Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-22T06:22:45.551Z Has data issue: false hasContentIssue false
  • English
  • Français

Butyrylcholinesterase and Cognitive Function

Published online by Cambridge University Press:  10 January 2005

Sultan Darvesh ,
Chris MacKnight  and
Kenneth Rockwood
Sultan Darvesh
Affiliation:
Department of Medicine, Divisions of Neurology, Dalhousie University, Halifax, Nova Scotia, Canada Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Chris MacKnight
Affiliation:
Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Kenneth Rockwood
Affiliation:
Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Get access Rights & Permissions [Opens in a new window]

Abstract

Butyrylcholinesterase (BuChE) is expressed in brain structures involved in cognition, but the effect of selective BuChE inhibitors on human cognitive function is unknown. We report a patient whose cognitive function deteriorated following a reduction and improved following reinstitution of ethopropazine, a selective BuChE inhibitor. We suggest that, because neurons expressing BuChE may be involved in cognition, there is merit to further evaluation of selective BuChE inhibitors in treating cognitive dysfunction.

Keywords

CholinesteraseethopropazineAlzheimer
Type
Articles
Information
International Psychogeriatrics , Volume 13 , Issue 4 , December 2001 , pp. 461 - 464
Copyright
© 2001 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)